Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.

Matsunaga N, Ufuk A, Morse BL, Bedwell DW, Bao J, Mohutsky MA, Hillgren KM, Hall SD, Houston JB, Galetin A.

Drug Metab Dispos. 2019 Mar;47(3):215-226. doi: 10.1124/dmd.118.084194. Epub 2018 Dec 28.

PMID:
30593544
2.

In Vitro and In Vivo Correlation of Hepatic Fraction of Metabolism by P450 in Dogs.

Zhou X, Hui YH, Hudson L, Katyayan KK, Mohutsky MA, Hao J, Schober DA, Hembre EJ.

J Pharm Sci. 2019 Feb;108(2):1017-1026. doi: 10.1016/j.xphs.2018.09.012. Epub 2018 Sep 19.

PMID:
30244007
3.

Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance.

Kenny JR, Ramsden D, Buckley DB, Dallas S, Fung C, Mohutsky M, Einolf HJ, Chen L, Dekeyser JG, Fitzgerald M, Goosen TC, Siu YA, Walsky RL, Zhang G, Tweedie D, Hariparsad N.

Drug Metab Dispos. 2018 Sep;46(9):1285-1303. doi: 10.1124/dmd.118.081927. Epub 2018 Jun 29.

PMID:
29959133
4.

Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water-soluble drugs.

Tres F, Posada MM, Hall SD, Mohutsky MA, Taylor LS.

Int J Pharm. 2018 May 30;543(1-2):29-37. doi: 10.1016/j.ijpharm.2018.03.038. Epub 2018 Mar 20.

PMID:
29572154
5.

Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence Techniques.

Tres F, Hall SD, Mohutsky MA, Taylor LS.

J Pharm Sci. 2018 Jan;107(1):94-102. doi: 10.1016/j.xphs.2017.10.002. Epub 2017 Oct 12.

PMID:
29031978
6.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.

Rougée LRA, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD.

Drug Metab Dispos. 2017 Sep;45(9):1008-1018. doi: 10.1124/dmd.117.076331. Epub 2017 Jul 5.

PMID:
28679672
7.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.

Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D.

Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23.

PMID:
28646080
8.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates.

Rougée LR, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD.

Drug Metab Dispos. 2016 Nov;44(11):1819-1827. Epub 2016 Sep 2.

PMID:
27590024
9.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.

Zhou X, Rougée LR, Bedwell DW, Cramer JW, Mohutsky MA, Calvert NA, Moulton RD, Cassidy KC, Yumibe NP, Adams LA, Ruterbories KJ.

Drug Metab Dispos. 2016 Aug;44(8):1184-92. doi: 10.1124/dmd.116.070623. Epub 2016 May 23.

PMID:
27217490
10.

In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.

Moulton RD, Ruterbories KJ, Bedwell DW, Mohutsky MA.

Drug Metab Dispos. 2015 May;43(5):756-61. doi: 10.1124/dmd.114.062893. Epub 2015 Mar 9.

PMID:
25755052
11.

Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk.

Zamek-Gliszczynski MJ, Mohutsky MA, Rehmel JL, Ke AB.

Drug Metab Dispos. 2014 Jun;42(6):1008-15. doi: 10.1124/dmd.114.057018. Epub 2014 Mar 21.

PMID:
24658455
12.

Irreversible enzyme inhibition kinetics and drug-drug interactions.

Mohutsky M, Hall SD.

Methods Mol Biol. 2014;1113:57-91. doi: 10.1007/978-1-62703-758-7_5. Review.

PMID:
24523109
13.

Reversible mechanisms of enzyme inhibition and resulting clinical significance.

Ring B, Wrighton SA, Mohutsky M.

Methods Mol Biol. 2014;1113:37-56. doi: 10.1007/978-1-62703-758-7_4. Review.

PMID:
24523108
14.

Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate.

Taxak N, Desai PV, Patel B, Mohutsky M, Klimkowski VJ, Gombar V, Bharatam PV.

J Comput Chem. 2012 Aug 5;33(21):1740-7. doi: 10.1002/jcc.23008. Epub 2012 May 21.

PMID:
22610824
15.

Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2012 Apr;40(4):706-16. doi: 10.1124/dmd.111.043158. Epub 2012 Jan 6.

PMID:
22228749
16.

Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.

Danielson ML, Desai PV, Mohutsky MA, Wrighton SA, Lill MA.

Eur J Med Chem. 2011 Sep;46(9):3953-63. doi: 10.1016/j.ejmech.2011.05.067. Epub 2011 Jun 23.

17.

Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2011 Apr;39(4):591-602. doi: 10.1124/dmd.110.036400. Epub 2011 Jan 6.

PMID:
21212240
18.

Introduction to hepatic drug metabolizing enzyme induction in drug safety evaluation studies.

Botts S, Ennulat D, Francke-Carroll S, Graham M, Maronpot RR, Mohutsky M.

Toxicol Pathol. 2010 Aug;38(5):796-8. doi: 10.1177/0192623310374330. Epub 2010 Jul 9.

PMID:
20622194
19.

Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.

Mohutsky MA, Romeike A, Meador V, Lee WM, Fowler J, Francke-Carroll S.

Toxicol Pathol. 2010 Aug;38(5):799-809. doi: 10.1177/0192623310375099. Epub 2010 Jul 8. Review.

PMID:
20616377
20.

Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.

Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD.

J Pharmacol Exp Ther. 2008 Oct;327(1):248-57. doi: 10.1124/jpet.108.139998. Epub 2008 Jul 23.

PMID:
18650247
21.

Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation.

Hashizume T, Xu Y, Mohutsky MA, Alberts J, Hadden C, Kalhorn TF, Isoherranen N, Shuhart MC, Thummel KE.

Biochem Pharmacol. 2008 Mar 1;75(5):1240-50. doi: 10.1016/j.bcp.2007.11.008. Epub 2007 Nov 22.

22.

Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Mohutsky MA, Chien JY, Ring BJ, Wrighton SA.

Pharm Res. 2006 Apr;23(4):654-62. Epub 2006 Mar 24.

PMID:
16550474
23.

Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo.

Mohutsky MA, Anderson GD, Miller JW, Elmer GW.

Am J Ther. 2006 Jan-Feb;13(1):24-31.

PMID:
16428919
24.

The use of a substrate cassette strategy to improve the capacity and throughput of cytochrome P450 induction studies in human hepatocytes.

Mohutsky MA, Petullo DM, Wrighton SA.

Drug Metab Dispos. 2005 Jul;33(7):920-3. Epub 2005 Mar 31.

PMID:
15802386
25.

Physiological approaches to the prediction of drug-drug interactions in study populations.

Chien JY, Mohutsky MA, Wrighton SA.

Curr Drug Metab. 2003 Oct;4(5):347-56. Review.

PMID:
14529367
26.

Possible interaction between warfarin and Lycium barbarum L.

Lam AY, Elmer GW, Mohutsky MA.

Ann Pharmacother. 2001 Oct;35(10):1199-201.

PMID:
11675844

Supplemental Content

Loading ...
Support Center